Brevilin A exhibits significant anti-inflammatory and anticancer activities. It has been studied for its ability to induce apoptosis in various cancer cell lines, including breast, lung, and liver cancer, by modulating key signaling pathways such as JAK/STAT and PI3K/AKT. The compound also shows potential in suppressing tumor growth and metastasis by inhibiting cell migration and invasion. Additionally, Brevilin A demonstrates immunomodulatory effects, making it a candidate for further research in autoimmune diseases and chronic inflammation. Its natural origin and potent bioactivity support its development as a lead compound in pharmaceuticals targeting cancer and inflammatory disorders.